The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
Brasil/CT
Advised Brasil/CT on a capital injection made by Invest Tech in the Company. Brasil/CT specializes in the e-commerce market and is a leader in B2C and B2B full-commerce and loyalty operations in Brazil. Invest Tech is an investment manager focused on venture capital and private equity in the technology and telecom sectors
Elavon do Brasil
Advised Minneapolis-based US Bancorp, the fifth largest commercial bank in the United States, and the parent company of Elavon, Inc., in the sale of its 50.1 percent majority stake in São Paulo-based, Elavon do Brasil to Stone Pagamentos, a local market, privately-held merchant acquirer.
Policard
Advised Policard, one of the largest electronic payment companies in Brazil, on the combination of its business with the Brazilian operations of Groupe Up, one of the leading employee benefits, public, social and loyalty programs providers in the world
Recepta Biopharma
Advised Recepta Biopharma on a capital raise
Allied Healthcare
Advised Saga plc on the disposal of Allied Healthcare, the leading local authority-funded domiciliary care business in the UK, to AURELIUS Investments
Allergan Generics
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
Portfolio of GlaxoSmithKline plc consumer and OTC brands
Advised GlaxoSmithKline plc, a leading British pharmaceutical company, on the disposal of a portfolio of consumer and OTC brands to Omega Pharma NV, a subsidiary of Perrigo Company plc
Refinancing of syndicated bank debt facilities
Advised Primary Health Care on the refinancing of its A$1.25 billion syndicated bank debt facilities
Hitachi Appliances, Inc.
Advised Hitachi, LTD / Hitachi Appliances, Inc, a leading global industrial conglomerate focused on information and telecommunications systems, power systems and social systems, on their formation of a global HVAC joint venture with Johnson Controls
Clinuvel Pharmaceuticals Limited
Advised Clinuvel, a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders, in response to an unsolicited proposal to acquire the business from Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases
Frank Russell Company
Advised LSEG on the proposed acquisition of Frank Russell Company, the number one provider of benchmarks to US-focused equity funds and a leading provider of multi-asset class investment solutions, from Northwestern Mutual Life Insurance Company, including acting as Joint Sponsor to LSEG on its $1.6 billion rights issue
Investec Bank (Australia) Limited
Advised Investec Bank (Australia) Limited on the sale of its Professional Finance and Asset Finance and Leasing businesses, its deposit book, and its Australian banking licence to Bank of Queensland Limited (“BOQ”). BOQ is a leading regional Australian bank which provides retail and business banking
Unfors Raysafe AB
Advised the Sixth Swedish National Pension Fund on the sale of Unfors Raysafe AB, a provider of easy-to-use products that help to reduce unnecessary radiation exposure, to Fluke Biomedical Corp., a subsidiary of Danaher Corp. that manufactures biomedical test and simulation products
CPP Group plc
Advised on the comprehensive restructuring of its balance sheet, including sale of the US business, terming out the existing RCF and creation of additional liquidity by the long term deferral of business partner payments
A$1.6bn non-core loan portfolio
Advised Suncorp Group Ltd (ASX:SUN), a leading general insurance, retail banking and life insurance group in Australia and New Zealand, on the sale of a A$1.6bn portfolio of performing and non-performing (corporate and property) loans to Goldman Sachs Group Inc., an American multinational investment banking firm
iSelect (30% shareholding)
Advised Mi9, a joint venture between Microsoft and Nine Entertainment Co, and one of Australia’s leading digital media companies, on the sale of its 30% holding in iSelect, a leading Australian online-driven comparison service, as part of the Initial Public Offering of iSelect
d-cyphaTrade Limited
Advised Transpower New Zealand, the state owned owner-operator of New Zealand’s electricity distribution network on the sale of its wholly owned subsidiary d-cyphaTrade Limited to the Australian Securities Exchange. d-cyphaTrade specializes in the design and marketing of Australian electricity derivatives traded on the ASX24 derivatives platform
Warner Chilcott, plc
Advised Actavis, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, branded and biosimilar products on its acquisition of Warner Chilcott plc
Sanyo DI Solution
Advised Advantage Partners, a leading private equity fund in Japan, on the acquisition of 100% stake in Sanyo DI Solution, the digital still camera OEM business in SANYO Electric, a group company of Panasonic
Investments of AP Alternative Assets, L.P.
Advised the Special Committee of the Conflicts Committee of the Board of Directors of Athene Holding Ltd. in connection with the purchase of non-cash investment assets of AP Alternative Assets L.P.
iNova Pharmaceuticals
Advised Archer Capital and Ironbridge Capital on the sale of iNova Pharmaceuticals, a leading pharmaceuticals company that sells and distributes a range of prescription and over-the-counter products in Australia, New Zealand, Asia and Southern Africa, to Valeant Pharmaceuticals
Northern Rock
Advised Virgin Money, a financial services provider, on the acquisition of Northern Rock, a UK retail mortgage and savings bank, from UK Financial Investments Ltd, which manages the UK Government’s investments in financial institutions
Mako Global Derivatives Executive LLP
Advised Close Brothers Group plc, an independent financial services group, on the sale of its 49.9% stake in Mako Global, a market maker in exchange traded derivatives, to Mako’s management
Diabetes-related patent estate and royalty stream of Astellas Pharma subsidiary, Prosidion
Advised Royalty Pharma, a leading acquiror of biopharmaceutical royalty interests, on the acquisition of the DPP-IV patent estate and associated royalty stream of Astellas Pharma subsidiary, Prosidion
Bionomics Ltd
Advised Bionomics Ltd, in relation to the tender process run by Bionomics’ largest shareholder, Start-up Australia Ventures (“Start-up”), for its 28% stake in the company, follow on sell-down of Start-up’s stake to 8% and associated capital raising by Bionomics